Cost-effectiveness of pioglitazone in patients with type 2 diabetes and a history of macrovascular disease in a Swiss setting

KM Erny-Albrecht; E Erdmann

doi:10.4414/smw.2009.12381

Original article

Vol. 139 No. 1112 (2009)

Cost-effectiveness of pioglitazone in patients with type 2 diabetes and a history of macrovascular disease in a Swiss setting

KM Erny-Albrecht
E Erdmann

Fulltext PDF

DOI: https://doi.org/10.4414/smw.2009.12381
Cite this as:: Swiss Med Wkly. 2009;139:173-173
Published: 21.03.2009

How to Cite

1.

Erny-Albrecht K, Erdmann E. Cost-effectiveness of pioglitazone in patients with type 2 diabetes and a history of macrovascular disease in a Swiss setting. Swiss Med Wkly [Internet]. 2009 Mar. 21 [cited 2024 Nov. 22];139(1112):173-. Available from: https://smw.ch/index.php/smw/article/view/956

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.